Protein expression
PD-L1
PD-L1 is a protein expression biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (15), each linked to its source.
Matched identity
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
FDA companion diagnostic
An FDA-cleared or approved companion diagnostic names this biomarker.
Source-level evidence only
Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.
FDA companion diagnostic assertions (15)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| PD-L1 IHC 28-8 pharmDx | PD-L1 | Agilent Technologies, Inc. | Esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma | 2026-07-01 |
| PD-L1 IHC 22C3 pharmDx | PD-L1 | Agilent Technologies, Inc. | Esophageal or Gastroesophageal Junction (GEJ) Carcinoma | 2026-02-11 |
| PD-L1 IHC 22C3 pharmDx | PD-L1 | Agilent Technologies, Inc. | Epithelial Ovarian, Fallopian Tube Cancer, or Primary Peritoneal Carcinoma (EOC) | 2026-02-10 |
| PD-L1 IHC 22C3 pharmDx | PD-L1 | Dako North America, Inc. | Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | 2023-11-07 |
| Ventana PD-L1 (SP263) Assay | PD-L1 | Ventana Medical Systems, Inc. | Non-Small Cell Lung Cancer (NSCLC) | 2023-03-01 |
Showing 5 of 15 companion diagnostic entries.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and assay-provider ledger.